- Home
- PRME vs RLAY Comparison
PRME vs RLAY Comparison
Compare PRME & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- RLAY
- Stock Information
- Founded
- PRME 2019
- RLAY 2015
- Country
- PRME United States
- RLAY United States
- Employees
- PRME N/A
- RLAY N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRME Health Care
- RLAY Health Care
- Exchange
- PRME Nasdaq
- RLAY Nasdaq
- Market Cap
- PRME 784.4M
- RLAY 803.4M
- IPO Year
- PRME 2022
- RLAY 2020
- Fundamental
- Price
- PRME $3.77
- RLAY $6.15
- Analyst Decision
- PRME Buy
- RLAY Strong Buy
- Analyst Count
- PRME 6
- RLAY 9
- Target Price
- PRME $9.50
- RLAY $16.00
- AVG Volume (30 Days)
- PRME 3.8M
- RLAY 2.1M
- Earning Date
- PRME 11-07-2025
- RLAY 11-06-2025
- Dividend Yield
- PRME N/A
- RLAY N/A
- EPS Growth
- PRME N/A
- RLAY N/A
- EPS
- PRME N/A
- RLAY N/A
- Revenue
- PRME $5,977,000.00
- RLAY $8,355,000.00
- Revenue This Year
- PRME $179.58
- RLAY $27.30
- Revenue Next Year
- PRME N/A
- RLAY $7.43
- P/E Ratio
- PRME N/A
- RLAY N/A
- Revenue Growth
- PRME 647.13
- RLAY N/A
- 52 Week Low
- PRME $1.11
- RLAY $1.78
- 52 Week High
- PRME $6.94
- RLAY $7.64
- Technical
- Relative Strength Index (RSI)
- PRME 36.50
- RLAY 45.56
- Support Level
- PRME $4.13
- RLAY $6.64
- Resistance Level
- PRME $5.03
- RLAY $7.42
- Average True Range (ATR)
- PRME 0.43
- RLAY 0.44
- MACD
- PRME -0.18
- RLAY -0.19
- Stochastic Oscillator
- PRME 8.74
- RLAY 8.31
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).